Business
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
CHICAGO, June 18, 2025--MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/9613f302a20a4f2f0c8bdfc14be4af43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3W5K2ALoEyewewvOdIQ3.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9613f302a20a4f2f0c8bdfc14be4af43","width":960,"height":365},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/QNstXnx5Djztv92iGvqhxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD03NjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/9613f302a20a4f2f0c8bdfc14be4af43","width":1000,"height":380}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatments","length":138,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":138,"olType":false},{"type":"text","content":"CHICAGO, June 18, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its entry into a clinical master supply agreement with Roche for future studies investigating the combination of MAIA’s telomere-targeting agent ateganosine (THIO), sequenced with Roche’s checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers.","length":502,"tagName":"p"},{"type":"text","content":""In preclinical studies, ateganosine was found to be highly synergistic and effective in combination with Roche’s anti-PD-L1 agent atezolizumab," said MAIA Chairman and CEO Vlad Vitoc, M.D. "We are pleased to partner with world-renowned Roche and we look forward to further strengthening our mission to find safe and effective cancer treatments."","length":366,"tagName":"p"},{"type":"text","content":"About Ateganosine","length":17,"tagName":"p"},{"type":"text","content":"Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a...